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Abstract
Background: Breast cancer accounts for 30.3% of all cancer types in Kuwaiti women. Death
occurs in approximately 43% of these patients. Our goal was to conduct a comprehensive analysis
of the pathobiological characteristics of the tumours in an attempt to determine any particular
trend that could be present.
Methods: One hundred and sixty-six cases were included in this study. All the pathology reports
and paraffin blocks pertaining to these cases were collected. Four micrometer sections were taken
from each block, and immunostaining against Her-2, ER, and PgR was performed. Both the
proportion and intensity of immunostaining were scored according to the Allred's method, and
typing of the tumour was done according the WHO criteria regarding tumour classification.
Grading of invasive carcinomas was done according to the modified Bloom-Richardson-Elston's
method, and tumour stage was determined according to the criteria set by the American Joint
Committee on Cancer.
Results: The mean age of the patients below 55 years was 40, as compared to 68 for those above
55 (p < 0.0001). More than half of the cases were in the right breast, and were surgically treated
by total mastectomy with axillary clearance. The majority of the tumours had irregular (stellate)
margins, was invasive, and had a surrounding breast tissue of adenosis or fibrocystic type. Their
mitotic index was 10–20 or >20 with a marked to moderate nuclear pleomorphism. They were
mostly grade II or III, sized 2–5 or > 5 cm, had absent or scanty tumour lymphocytes, and were
stage II or III. The in situ tumours were mainly ductal carcinoma (DCIS) of which comedo and
cribriform were the major histological subtypes. The major histological subtypes of the invasive
tumours were ductal-not otherwise specified, lobular, and tubular/cribriform. In this study, we also
found a significant (p < 0.05) association between over expression of Her-2, lack of expression of
ER and some of the characteristics mentioned above.
Conclusion: Breast cancer in Kuwait seems to be more aggressive than what is currently seen in
Europe, North America, Australia, and parts of Asia. Further investigations regarding the features
observed in this study need to be performed.
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Introduction
The Kuwaiti population is a growing one, and so is the
incidence of cancer among the Kuwaitis. In females, the
most common types of malignancies include breast can-
cer, followed by thyroid cancer, cervical uteri and colorec-
tal carcinomas, and ovarian cancer. Breast cancer accounts
for 30.3% of all cancer types, and death occurs in approx-
imately 43% of patients [1].
The amount of research addressing breast carcinoma in
Kuwait is still minimal, and nation-wide studies are still
lacking. Accordingly, little is known so far about the dis-
ease. Based on our clinical encounters with breast cancer
patients at Mubarak al-Kabeer Hospital, which is one of
the five major public hospitals in the State of Kuwait, we
have noticed that these patients seem to be presenting at
a relatively young age with the disease at an advanced
stage. Therefore, we sought to conduct a comprehensive
analysis of the pathobiological characteristics of the
tumours in an attempt to provide the clinicians with a bet-
ter picture about the biological behaviour of the tumours
including any particular trend that could be present. This
could hopefully help the clinicians better understand the
disease manifestation in the Kuwaiti population, and,
accordingly, help them develop a platform on which fur-
ther disease investigation and clinical management strate-
gies could be based.
In this study, we put much emphasis on carefully examin-
ing the pathobiological characteristics of the tumour.
These characteristics included tumour margin, histologi-
cal types and subtypes, tumour surrounding breast tissue
type, tumour grade, mitotic index, tumour size, nuclear
pleomorphism, stage of the disease, lymphocyte involve-
ment, breast laterality, nature of surgical management
(operation performed), and degree of expression of the
prognostic markers Her-2, oestrogen receptor (ER), and
progesterone receptor (PgR). We also investigated any
possible significant association between each of the above
characteristics and the degree of expression of Her-2, ER,
and PgR.
Methods
One hundred and sixty-six breast cancer cases seen at
Mubarak Al-Kabeer Hospital, were reviewed. All the
pathology reports and the H&E slides pertaining to these
cases were collected. We selected the cases where complete
information regarding the patient and the tumour were
available. The Mubarak Al-Kabeer Hospital provides
annual health care to around 750,000 people living in the
Mubarak Al-Kabeer, Hawally, Salmiya, and Jabriya dis-
tricts. The study was approved by the Human Ethics Com-
mittee at the Faculty of Medicine, Health Science Centre,
Kuwait University, and it conformed to the provisions of
the Declaration of Helsinki.
For immunohistochemical staining, the following stand-
ard procedure was followed [2]. Sections were cut at 4 μm
thickness, mounted onto silane-coated slides
(S21.1910.110, Novocastra, Newcastle upon Tyne, UK),
and left to dry overnight at 37°C. They were then depar-
affinized, re-hydrated, and underwent antigen retrieval
(Epitope Retrieval PH6, RE7115, Novocastra) by micro-
waving (Daewoo KOR-161G, 1000 W, 2450 MHz, 10
power levels, Seoul, South Korea) for 20 minutes. After
cooling down to room temperature, the sections were
incubated for 15 minutes with 3% hydrogen peroxide to
block any endogenous peroxidase activity, washed with
TBS, and incubated with goat serum (NCL-G-SERUM,
Novocastra) for 20 minutes to block any non-specific
staining. They were then washed with TBS, and incubated
with 200 μl of primary antibodies for 1 hour at 37°C in a
humidified rotator. The dilution of the primary antibody
against Her-2 (Clone 10A7, NCL-CBE-356, Novocastra)
was 1:40, while those of ER (Clone 6F11, NCL-ER-6F11,
Novocastra) and PgR (Clone 16, NCL-PgR-312, Novocas-
tra) were 1:40 and 1:100, respectively. The sections were
then washed with TBS, and incubated with the secondary
link antibody (Novolink Max RE7280-K, Novocastra) for
30 minutes. This was followed by washing with TBS and
incubation with the tertiary antibody (Novolink Max
RE7280-K, Novocastra) for 30 minutes. Finally, the sec-
tions were washed with TBS and incubated for 10 minutes
with DAB (Novolink Max RE7280-K, Novocastra) chro-
mogen contrasted with hematoxylin counterstain. Posi-
tive and negative control slides were used in each staining
experiment. The positive controls were breast carcinomas
known to be positive for Her-2, ER, and PgR. The negative
controls included sections of breast carcinomas known to
be negative for Her-2, ER, and PgR, and sections taken
from the same tissue block but incubated with antibody
diluent instead of the primary antibody.
The scoring system developed by Allred et al. [2] in rela-
tion to ER, PgR, and Her-2 staining was followed. Accord-
ingly, both the proportion and intensity of staining are
taken into consideration. A proportion score indicated the
proportion of positive tumour cells on the entire slide,
and it ranged from 0 to 5. An intensity score indicated the
average staining intensity of positive tumour cells, and it
ranged from 0 to 3. Both scores were then added, to
obtain a total score ranging from 0 to 8. This scoring sys-
tem has been followed in numerous experiments and has
resulted in an inter- and intra observer reproducibility of
more than 90% [2]. Based on this scoring system, any
total score between 6 and 8 was considered overexpres-
sion in our study. If the total score was 0, the tumour was
considered lacking expression.
The tumours were typed according to the WHO classifica-
tion system [3]. Although it is beyond the scope of thisJournal of Carcinogenesis 2007, 6:12 http://www.carcinogenesis.com/content/6/1/12
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manuscript to provide details of such classification, we
will summarize the major points. To start with, such clas-
sification includes invasive versus non-invasive breast car-
cinomas, based on the infiltration of the basal membrane
by the tumour cells. The non-invasive carcinomas are clas-
sified as ductal carcinoma in situ (DCIS) or lobular carci-
noma in situ (LCIS), based on the involvement of the
ducts or the lobules forming the breast tissue. The DCIS
tumours include the following subtypes based on the
morphology: comedo, cribriform, solid, papillary, micro-
papillary, and apocrine. The invasive tumours are further
classified as ductal-not otherwise specified, lobular, tubu-
lar/cribriform, colloid (mucinous), medullary, papillary,
comedo, Paget's disease, adenoid, and apocrine.
The modified Bloom-Richardson-Elston histological sys-
tem was used for grading the invasive carcinomas [4]. This
aims at examining the growth pattern as well as the bio-
logical characteristics of differentiation of these carcino-
mas. Accordingly, the following criteria were used:
1) Formation of the gland tubules and acini
a) characteristic formation of tubules (>75%) = 1 point
b) moderate formation of tubules (10–75%) = 2 points
c) little or without tubules at all (<10%) = 3 points
2) Pleomorphism of cancer cell nuclei (abnormalities in
size, structure, and shape)
a) isomorphism of nuclei or small variability in shape,
size, and structure of nuclei = 1 point
b) moderate variability in shape, size, and structure of
nucleus = 2 points
c) marked characteristic polymorphism = 3 points
3) Mitosis per 10 high power fields
a) <10 mitosis = 1 point
b) 10–20 mitosis = 2 points
c) >20 mitosis = 3 points
By adding up the points of the above criteria, the level of
tumour differentiation could then be calculated as fol-
lows: grade I (well differentiated; 3–5 points), grade II
(moderately differentiated; 6–7 points), grade III (poorly
differentiated; 8–9 points).
As far as staging the carcinomas is concerned, we followed
the criteria set by the American Joint Committee on Can-
cer [5] and which include briefly:
Stage 0: LCIS or DCIS;
Stage I: invasive carcinoma ≤ 2 cm in diameter without
nodal involvement;
Stage II: invasive carcinoma ≤ 5 cm in diameter with up to
three involved axillary nodes, or invasive carcinoma > 5
cm without nodal involvement;
Stage III: invasive carcinoma ≤ 5 cm in diameter with four
or more involved axillary nodes, or invasive carcinoma >
5 cm in diameter with nodal involvement, or invasive car-
cinoma with ≥ 10 involved axillary nodes, or invasive car-
cinoma with involvement of the ipsilateral internal
mammary lymph nodes, or invasive carcinoma with skin
involvement, chest wall fixation, or clinical inflammatory
carcinoma;
Stage IV: any distant metastases.
The common standard international approach among
pathologists for measuring tumour size was followed in
this study. Accordingly, we used the largest diameter of
the cut surface of the tumour, and we made much of the
diameter of the invasive component. Therefore, we made
use of the largest size of the invasive component on the
cut surface.
Statistical analysis
The Student's t-test was used for comparison of patient
age. The chi square (x2) test was used to compare the asso-
ciation of expression of Her-2, ER, and PgR and the mac-
roscopic and microscopic characteristics of the tumours.
The results were considered statistically significant if the p
value was < 0.05.
Results
Age and association with Her-2, ER, and PgR expression 
(Additional File 1, 2)
The age-world-standardized incidence rate of breast can-
cer in Kuwaitis is 31.8, which is higher than that of neigh-
bouring Gulf countries such as the United Arab Emirates
(24.1) and Saudi Arabia (24.7) [1]. Our results showed
that 68.1% of the patients were between the age of 30 to
55 yrs, 29.5% above 55 yrs, and 2.4% below 30 yrs. The
mean age of the patients below 55 yrs was 40, as com-
pared to 68 for those above 55 (p < 0.0001).
There was a significant association between over expres-
sion of Her-2 and age of the patients, whereby 78.8% of
the patients aged 30–55 years and 75% of the patientsJournal of Carcinogenesis 2007, 6:12 http://www.carcinogenesis.com/content/6/1/12
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aged less than 30 years were Her-2 positive (p = 0.0003).
A similar age trend but with different expression was
observed with ER expression, since 81.4% of the patients
aged 30–55 yrs and 75% of those aged less than 30 yrs
were ER negative (p < 0.0001). Patients aged above 55 yrs
were more ER positive (61.2%). On the other hand, no
significant association between the different age groups
and PgR expression was observed (p = 0.36).
Pathobiological characteristics and association with Her-
2, ER, and PgR expression (Additional File 2, 3)
The percentage distribution of cancer lesions did not dif-
fer between the right (53.6%) and left (42.2%) breasts,
but 87.6% of the ones in the right breast were significantly
associated with over expression of Her-2 (p < 0.0001). A
similar association was seen with lesions present in both
the right and left breasts, but the number was too small (n
= 7) to deduce any conclusions. Also, six out of seven cases
where the cancer lesion was present in both breasts were
ER negative, but, again, the number was too small to make
any comments.
Various types of surgical management were seen in our
study, but the most common ones were total mastectomy
with axillary clearance (53.6%) and total lumpectomy
without axillary clearance (29.5%). The majority of the
former were Her-2 positive (94.4%), ER negative (87.6%),
and PgR negative (84.3%), and a significant association
was found (p < 0.0001). A similar trend was seen in
patients who underwent total lumpectomy with axillary
clearance, but the total number in this group did not
exceed seven cases. No significant association was
observed in patients who underwent total lumpectomy
without axillary clearance and Her-2, ER, and PgR expres-
sion.
The tumour margins studied were irregular (stellate), and
defined (demarked). The former accounted for 87.9% of
all the breast cancer cases, and it was associated with over
expression (89%) of Her-2 (p < 0.0001) and with negative
expression (82.2%) of ER (p = 0.0011). No association
was seen with PgR expression (p = 0.55).
Our results showed that 83.1% of the tumours were inva-
sive as compared to 16.9% of in situ tumours. The invasive
tumours were predominantly Her-2 positive (87%), and
ER (79.7%) and PgR negative (71%) (p < 0.0001). On the
other hand, the in situ tumours were predominantly Her-
2 negative (92.9%), and ER (85.7%) and PgR (71.4%)
positive. The in situ tumours were either ductal or lobular.
The ductal ones significantly over expressed Her-2 and
were ER negative (p < 0.001).
The breast tissue type surrounding the tumour was either
adenosis (51.2%), fibrocystic (44%), normal (3.6%), or
papillomatous (1.2%). Eighty nine percent of the
tumours which were surrounded by fibrocystic tissue over
expressed Her-2 (p < 0.0001) and were ER negative (p =
0.0004). On the other hand, 100% and 83.3% of the nor-
mal type were Her-2 and ER negative respectively. No sig-
nificant association was observed with PgR expression (p
= 0.54).
Our results showed that 54.8% of the tumours had a
mitotic index of between 10 and 20, 28.3% above 20, and
16.9% below 10. Most of those with a mitotic index
between 10 and 20 (86.8%) and above 20 (89.4%) over
expressed Her-2 (p < 0.0001), and 84.6% and 85.1% were
ER negative respectively (p < 0.0001). Most of the ones
with a mitotic index below 10 were Her-2 negative
(78.6%) and ER positive (67.9%). No significant associa-
tion was observed between the mitotic index characteristic
and the degree of expression of PgR by the tumours (p =
0.31).
A marked nuclear pleomorphism was seen in 50.6% of
the cases we examined. Such pleomorphism was either
moderate or small in the remaining cases (38.5% and
10.8% respectively). The marked nuclear pleomorphism
was significantly associated with over expression of Her-2
(90.5%; p < 0.0001) and with negative ER expression
(89.3%; p < 0.0001). No significant association was
noticed with PgR expression (p = 0.76). As for the cases
where nuclear pleomorphism was small, 77.8% were Her-
2 negative and 66.7% were ER positive.
As far as tumour grade is concerned, 50.6% of the
tumours were grade II, 39.2% grade III, and 10.2% grade
I. The grade II and III tumours predominantly (92.9% and
87.7%, respectively) over expressed Her-2 and were ER
negative (95.2% and 84.6%, respectively). Grade I
tumours were mostly Her-2 negative (94.1%) and ER pos-
itive (82.3%). A significant association between tumour
grade and expression of Her-2 (p < 0.0001) and ER (p <
0.0001) but not PgR (p = 0.69) was observed.
The size of the tumour was between 2 and 5 cm in 53.6%
of the cases studied. The remaining cases had a tumour
size more than 5 cm (31.3%) and less than 2 cm (15.1%).
Similarly to the tumour grade and mitotic index indicated
above, most of the cases with a tumour size between 2 and
5 cm (84.3%) and more than 5 cm (92.3%) over
expressed Her-2 (p < 0.0001) and were ER negative
(80.9% and 88.5% respectively, p < 0.0001). In contrast
to tumour grade and mitotic index, most these cases were
also PgR negative (67.4% and 76.9% respectively, p =
0.016). Tumours smaller than 2 cm were mostly Her-2
negative (72%), and ER positive (80%).Journal of Carcinogenesis 2007, 6:12 http://www.carcinogenesis.com/content/6/1/12
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We examined the lymphocytes in the vicinity of or inside
the tumour, in an attempt to associate their presence/
absence with Her-2, ER, or PgR expression. We classified
the lymphocytes as follows: absent, scanty, multifocal
outside the tumour, multifocal inside the tumour, band
outside the tumour, band inside the tumour, diffuse out-
side the tumour, and diffuse inside the tumour. Most of
the tumours had lymphocytes either absent (34.3%),
scanty (25.9%), or multifocal outside the tumour
(10.8%). Our results did not show any significant associ-
ation between the above classification and Her-2 (p =
0.73), ER (p = 0.66), and PgR (p = 0.98) expression.
The most common tumour stage was stage II (39.8%), fol-
lowed by stage III (28.9%), stage I (16.9%), and stage IV
(14.5%). Our results showed that over expression of Her-
2 and lack of ER expression were mostly seen with stages
III and IV, whereby 81.2% and 85.4% of stage III tumours
over expressed Her-2 and were ER negative respectively (p
< 0.0001), and 87.5% and 75% of stage IV tumours over
expressed Her-2 and were ER negative respectively (p <
0.0001). No significant association was observed with
PgR expression (p = 0.41). Stage I tumours were mostly
Her-2 negative (78.6%) and ER positive (67.9%).
The histological subtypes of in situ ductal tumours
included comedo (47.8%), cribriform (26.1%), solid
(8.7%), papillary (8.7%), micropapillary (4.3%), and
apocrine (4.3%). Most of the comedo (81.8%) and cribri-
form (83.3%) subtypes over expressed Her-2, and a signif-
icant association was found (p = 0.004). A similar trend
was seen with ER expression, whereby 72.7% of the
comedo and 83.3% of the cribriform subtypes were ER
negative (p = 0.013). No significant association was found
between the above histological subtypes and PgR expres-
sion (p = 0.80).
The histological subtypes of invasive tumours included
ductal-not otherwise specified, lobular, tubular/cribri-
form, colloid (mucinous), medullary, papillary, comedo,
Paget's disease, adenoid, and apocrine. The most com-
mon histological subtypes were ductal-not otherwise
specified (71.7%), followed by lobular (10.1%), and
tubular/cribriform (9.4%). The ductal-not otherwise spec-
ified and lobular tumours were predominantly (89.9%
and 92.9% respectively) Her-2 positive and ER negative
(86.9% and 85.7% respectively). The tubular/cribriform
tumours were predominantly Her-2 negative (76.9%), ER
positive (84.6%), and PgR negative (61.5%). The chi
square test showed a significant association between the
most common histological subtypes mentioned above
and the expression of Her-2 and ER (p < 0.0001, and p =
0.0005 respectively). No significant association was
found with PgR expression (p = 0.23).
Discussion
The current trend in analysing the clinical outcome of a
patient with breast cancer is to examine predictive and
prognostic factors related to the patient and her tumour.
The former is related to the degree to which the patient
could respond to a specific therapy, while the latter is
related to the metastatic potential of the tumour. Several
studies have examined predictive and prognostic factors,
such as the age of the patient, tumour size, grade, prolifer-
ation, hormone status, histological type of the tumour,
and lymph node involvement, to name a few [6-11]. With
the advancement in science and technology, molecular
markers have been added to the above list, in an attempt
to help the clinicians to better monitor the course of the
disease and predict its outcome [10]. In this study, we
conducted a comprehensive analysis of breast carcinomas
taken from 166 patients in Kuwait. We limited our study
to a sample size of 166 because these were the only cases
for which we had complete information about the patient
and the tumour. Also, these were the only cases whose
paraffin blocks had enough tissue in them so that taking
extra sections from these blocks for our study did not
jeopardize the amount of tissue remaining in them in case
of future examination.
In contrast to what is commonly known about a rising
incidence of breast cancer with age, our results showed
that 70.5% of the patients we examined were young with
an age not exceeding 55 years. The mean age of these
patients was 40, and the majority of them were between
the ages of 30 and 55. This age distribution is significantly
younger than what is currently seen in Western and Arab
countries [1,11], and requires further careful examination
to determine the nature of the predisposing factor(s). One
possible explanation is that traditional marriages among
first-degree relatives in Kuwait are very common, and,
accordingly, hereditary factors could play a major role.
Another factor could be the degree of obesity associated
with a diet high in fat, carbohydrate, and protein, and lack
of exercise, which have been prevalent in Kuwait for the
past 20 years. We are in the process of conducting a com-
prehensive study at the Mubarak Al-Kabeer Hospital, in
order to examine the above and some other predisposing
factors. An interesting finding in this study is that the car-
cinomas from the patients in the above age category pre-
dominantly over express Her-2. These results confirm
those obtained from studies where an association
between age of breast cancer patients and their tumour
over expression of Her-2 was found [12-15]. Other stud-
ies, however, did not find any significant association
between the former and the latter [16,17]. We also found
that there is a significant association between the nature of
the tumours' expression of ER and the age of the patients.
Patients with ER negative tumours were mostly young (<Journal of Carcinogenesis 2007, 6:12 http://www.carcinogenesis.com/content/6/1/12
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30 years and between 30–55 years), as compared to posi-
tive ER expression in patients aged above 55 years.
Studies where an association between the nature of breast
carcinomas' expression of ER and age of the patients was
found have been documented. A recent study conducted
by Jalava et al. [18] reported a significant association
between the former and the latter. Ferno et al. [19]
reported a lower expression of ER in patients below 50
years old, and Quong et al. [20] found that the expression
of ER by breast carcinomas increases with age. Similar
findings to Quong were observed by Holdaway and
Mountjoy [21], Clark et al. [22], Wilking et al. [23],
Gaskell et al. [24], Rhodes et al. [25], and Tominaga et al.
[26]. Other studies have, however, found no association
between the age of the patient and the degree of expres-
sion of ER by the tumour [27].
In our study, we did not find any significant association
between the age of the patients and their tumour expres-
sion of PgR. Similar findings were reported by Holdaway
and Mountjoy [21], Clark et al. [22], and Wilking et al.
[23]. Other studies, however, have reported a higher
tumour expression of PgR in patients older than 59 years,
as compared to those between 50 and 59 years [19]. The
over expression of Her-2 and lack of ER expression by the
tumours of the patients aged below 55 years in our study
might explain the high mortality rate reported earlier [1]
among these patients, since such tumours often become
resistant to adjuvant and hormone therapies.
Other characteristics that we examined were the margins
of the tumours, laterality (right versus left breast), and the
type of surgical management. Tumour margins often rep-
resent a reliable source of positive or negative disease out-
come. In our study, the margins of the tumours were
mostly irregular (stellate). Having an irregular (stellate)
margin means that the tumour is not confined and there
is a potential for metastasis. This is further confirmed by
the degree of malignancy of the tumours, which was sig-
nificantly associated in our study with bad prognostic
markers such as over expression of Her-2 and negative
expression of ER. Irregular (stellate) margins did not asso-
ciate with PgR expression. An association between the
tumour margin status and Her-2, ER, or PgR expression
has been investigated in several studies [28-42]. Putti et al.
[29] recently demonstrated that breast tumours with a
pushing margin (another terminology for irregular or stel-
late margin) were found to be ER negative and over
expressing Her-2. A similar association with Her-2 over
expression was reported by Miller et al. [38]. The circum-
scription of the tumour margin was significantly associ-
ated with negative PgR expression in a study conducted on
281 women with breast cancer in Finland [30]. In another
study conducted on 980 patients with breast cancer, and
in which the patients were divided into three age catego-
ries (≤ 35 yrs, 36–50 yrs, and > 50 yrs), Fowble et al. [42]
reported that young patients had significantly more asso-
ciation between tumour margin status and negative ER
expression. Unlike our results, Kim et al. [37] reported an
association between tumour margin and positive rather
than negative ER expression: moreover, the authors found
an association with positive PgR expression. Lack of an
association between the tumour margin and hormone
receptor status was reported in a study conducted on 254
patients undergoing partial mastectomy [35]. Similarly,
Horiguchi et al. [31,33] found no association with
tumour expression of ER.
In our study, we also took breast laterality into considera-
tion. The number of carcinomas present in the right breast
was slightly more than in the left one (53.6% versus
42.2%). Such tumour laterality was significantly associ-
ated with Her-2 over expression, but not with ER or PgR
expression. However, since the difference in the location
of the carcinomas (right versus left breast) was not signif-
icant, we prefer not to deduce, at this stage, any conclu-
sions in relation to the expression of the above markers.
The small marginal difference in relation to the location
of the tumour in the right versus left breast in our study
was similar to the one reported by Largent et al. [43].
When analysing the demographic and tumour character-
istics of early breast cancer patients, the authors found
that 52% of the carcinomas were present in the right
breast, as compared to 48% in the left one. The only stud-
ies that we found in the literature, which attempted to
find an association between breast laterality and hormone
receptor expression were the ones conducted by Tominaga
et al. [26] and by Borisenkov and Bazhenov [44].
Borisenkov and Bazhenov reported that the degree of
expression of hormone receptors by breast carcinomas
taken from Russian patients significantly depended on
whether the tumour was present in the right or left breast
[44]. On the other hand, such an association was lacking
in the study conducted by Tominaga et al. [26] on Japa-
nese women with breast cancer. In our study, the percent-
age of patients who underwent total mastectomy with
axillary clearance was the highest. Interestingly, there was
a significant association between this type of surgical
management and the tumour expression of Her-2, ER,
and PgR. This association was also seen in the patients
who underwent total lumpectomy with axillary clearance.
The carcinomas of the patients in both surgical categories
predominantly over expressed Her-2, and were mostly ER
and PgR negative. According to our knowledge, this is the
first time where such an association has been reported.
The histological characteristics of breast carcinomas have
been investigated in several studies trying to correlate the
histological type/subtype of the tumour with the diseaseJournal of Carcinogenesis 2007, 6:12 http://www.carcinogenesis.com/content/6/1/12
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outcome such as local recurrence, site of recurrence (ipsi-
lateral versus bilateral), metastasis (regional versus dis-
tant), and response to therapy. For instance, even earlier
reports have shown that the 30-year survival rate of
women with certain histological types of breast cancer
such as tubular or lobular is greater than 60% as com-
pared with less than 20% for women with breast cancer of
no special type [45]. Chen et al. [46] have demonstrated
that breast cancer of lobular histological type is more
often bilateral when compared to other types.
In our study, we conducted a comprehensive histological
analysis of the breast tumours. Our results showed that
83.1% of the carcinomas were invasive. Eighty two per-
cent of the in situ carcinomas were ductal, and they were
predominantly comedo or cribriform. The invasive carci-
nomas were mostly ductal-not otherwise specified, lobu-
lar, or tubular/cribriform, and the breast tissue type
surrounding the carcinoma was predominantly adenosis
or fibrocystic. Our results are similar to those reported by
Andersson et al. [47], where the incidence of in situ breast
carcinoma was 16%, in contrast to a higher incidence
(26%) reported by May et al. [48]. When we analysed the
above parameters in relation to the tumour expression of
Her-2, ER, and PgR, we found that the invasive carcino-
mas predominantly over expressed Her-2 and were mostly
ER and PgR negative. On the other hand, the in situ
tumours were mostly Her-2 negative, and ER and PgR pos-
itive. This provides more evidence to the hypothesis that
aggressive tumours seem to lack hormone receptors and
to over express Her-2. Our results are similar to those
reported by Zafrani et al. [49], where 81% of the in situ
tumours the authors examined were ER positive and 73%
were PgR positive. We also found an association between
some histological subtypes of the in situ ductal tumours
and Her-2, ER, and PgR expression, whereby the comedo
and cribriform subtypes significantly over expressed Her-
2 and were ER negative. This is similar to the findings
reported by Janssens et al. [50] and by Provenzano et al.
[51], and confirms previous reports that showed lack of
ER expression in comedo histological subtype of ductal
carcinoma in situ [27]. As far as the histological subtypes
of invasive carcinoma are concerned, we found that the
most common subtypes were ductal-not otherwise speci-
fied, lobular, and tubular/cribriform. This confirms the
WHO classification of invasive breast carcinomas in rela-
tion to the percentage occurrence of these subtypes [3].
The ductal-not otherwise specified carcinomas over
expressed Her-2 and were predominantly ER negative.
This again shows the association between the nature of
the biological expression of Her-2 and ER by the tumour
and its degree of malignancy, since it has been argued that
ductal-not otherwise specified carcinomas are the most
aggressive type of breast cancer. This is based on the fact
that its tumour cells are often seen infiltrating into the sur-
rounding tissue, including perivascular and perineural
spaces, as well as lymphatic and blood vessels. We also
found a significant association between Her-2 over expres-
sion and lack of ER expression and the lobular histologi-
cal subtype. This could imply that, although this
histological subtype of invasive breast carcinoma is less
common than the ductal-not otherwise specified one,
lobular carcinomas could be equally aggressive. Various
and sometimes contradictory reports have been published
in the literature regarding the association between the
expression of Her-2 and hormone receptors and the vari-
ous histological subtypes of invasive breast carcinomas. In
a recent study conducted by Jalava et al. [18], the breast
carcinomas' ER expression was found to be greater in lob-
ular than in ductal tumours. Other authors have reported
that the mucinous type is associated with an increase in
the expression of ER and with a decrease in the expression
of Her-2 [52]. Similarly, Her-2 was found to be inversely
associated with ER status based on the histological type in
a study conducted by Coradini et al. [53]. Still, other stud-
ies confirmed a lack of an association between the histo-
logical type of breast tumour and its hormone receptor
status [54].
As far as other tumour characteristics are concerned, we
have noticed that tumours with a surrounding breast tis-
sue that is fibrocystic in nature commonly over expressed
Her-2. Whether there is a direct biological association
between the former and the latter remains to be investi-
gated.
Conclusion
Our above findings showed so far that tumour character-
istics in Kuwaiti patients are rather aggressive. In order to
further analyse the profile of these tumours, we examined
some important tumour-related prognostic factors, such
as grade, mitotic index, size, nuclear pleomorphism,
stage, and lymphocytes. The majority of our patients pre-
sented with grade II or III tumours. These two grades were
Her-2 positive and ER negative, in contrast to grade I
tumours which were Her-2 negative and ER positive. This
confirms the results of the study conducted by Keshgegian
[15], where Her-2 over expression was found to correlate
with higher tumour grade. Our results are also similar to
those reported by Armes et al. [55,56], where tumour
grade was found to correlate with over expression of Her-
2 and with negative ER expression. However, our finding
is not in agreement with the studies where a weak or no
association was found between the grade of the tumour
and its expression of Her-2, ER and/or PgR [15,22,27,54].
Interestingly, the same significant trend that we observed
in grade II and III tumours, in relation to association with
over expression of Her-2 and negative ER expression, was
also seen in tumours with a mitotic index of between 10
and 20 and above 20, and in tumours measuring betweenJournal of Carcinogenesis 2007, 6:12 http://www.carcinogenesis.com/content/6/1/12
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2 and 5 cm and above 5 cm. Similarly, tumours with
marked nuclear pleomorphism and those in stages III and
IV over expressed Her-2 and were ER negative. We did not
find significant association between Her-2, ER, and PgR
expression and the nature of presence or absence of
tumour lymphocytes. The literature has cited controver-
sial findings in relation to a possible association between
Her-2, ER, and PgR tumour expression and some of the
above prognostic parameters. Some studies have reported
that the expression of Her-2 and ER does not associate
with the size of the tumour [15,54], whereas others
reported a significant association with ER expression
[21,22,27]. For instance, the expression of ER was found
to be higher in small breast tumours, and to significantly
decrease in tumours above 5 cm [21,27]. Our study
showed that tumours which were above 5 cm in size were
ER negative, and so were those measuring between 2 and
5 cm. The high mitotic index that we observed, and which
was associated with both Her-2 over expression and nega-
tive ER, reflected a poor prognosis in our patients. Several
studies have reported similar association [15,18,27].
Finally, our results do not confirm earlier studies in which
the expression of ER was associated with the nature of the
presence of lymphocytes in the vicinity of the tumour
[57,58]. We chose to examine the nature of the presence
of tumour lymphocytes as one of the tumour characteris-
tics that we examined in this study, since such a character-
istic could provide an insight into the immunological
status of the tumour. The observations reported in some
types of tumours such as melanomas, which share with
breast carcinoma their epithelial origin, have shown that
tumours infiltrated by lymphocytes respond better to
therapy, as compared to those where the lymphocytes are
present outside the tumour (being in clusters or as a
band), and as compared to those where the lymphocytes
are absent [59,60]. According to our study, the expression
or lack of expression of Her-2, ER, and PgR does not seem
to have a direct effect on the nature of the location of lym-
phocytes in relation to the breast carcinomas that we
examined. This is a new finding according to our knowl-
edge.
In conclusion, breast cancer is currently affecting women
at a young age in Kuwait. The characteristics of the
tumours that we studied showed that they were more
aggressive than those reported in neighbouring and
regional countries. Our results seem to confirm the obser-
vation that over expression of Her-2 and lack of ER expres-
sion correlate with a degree of malignancy of breast
tumours which lead to poor prognosis and resistance to
therapy. Our results also argue for the necessity of estab-
lishing awareness of the disease in Kuwaiti society, along
with further investigating its molecular pathogenesis.
Additional material
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